Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
BACKGROUND: To assess potentially elevated cardiovascular risk related to new antihyperglycemic drugs in patients with type 2 diabetes, regulatory agencies require a comprehensive evaluation of the cardiovascular safety profile of new antidiabetic therapies. We assessed cardiovascular outcomes with alogliptin, a new inhibitor of dipeptidyl peptidase 4 (DPP-4), as compared with placebo in patients with type 2 diabetes who had had a recent acute coronary syndrome. METHODS: We randomly assigned patients with type 2 diabetes and either an acute myocardial infarction or unstable angina requiring hospitalization within the previous 15 to 90 days to receive alogliptin or placebo in addition to existing antihyperglycemic and cardiovascular drug therapy. The study design was a double-blind, noninferiority trial with a prespecified noninferiority margin of 1.3 for the hazard ratio for the primary end point of a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. RESULTS: A total of 5380 patients underwent randomization and were followed for up to 40 months (median, 18 months). A primary end-point event occurred in 305 patients assigned to alogliptin (11.3%) and in 316 patients assigned to placebo (11.8%) (hazard ratio, 0.96; upper boundary of the one-sided repeated confidence interval, 1.16; P<0.001 for noninferiority). Glycated hemoglobin levels were significantly lower with alogliptin than with placebo (mean difference, -0.36 percentage points; P<0.001). Incidences of hypoglycemia, cancer, pancreatitis, and initiation of dialysis were similar with alogliptin and placebo. CONCLUSIONS: Among patients with type 2 diabetes who had had a recent acute coronary syndrome, the rates of major adverse cardiovascular events were not increased with the DPP-4 inhibitor alogliptin as compared with placebo. (Funded by Takeda Development Center Americas; EXAMINE ClinicalTrials.gov number, NCT00968708.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“DPP-4 inhibitors do not have significant GI adverse effects and may be used in early combination with metformin.1038–1043”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1038]
In the citing paper
“There are a number of other trials regarding cardiovascular outcomes in high-risk cohorts of patients with type 2 diabetes in which similar magnitude effects on glycemic control have been shown but without significant benefits with respect to rates of cardiovascular events or death.”
From Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (2016) · cites this paper as [20]
In the citing paper
“Pharmaceutical interventions of 1.5 to 3 years duration report HbA1c reductions of 0.2 to 1.0% with DPP-4 inhibitors, SGLT-2 inhibitors and GLP-1 agonists (6, 7, 49).”
In the citing paper
“GLP-1 agents, including dipeptidyl peptidase-4 (DPP-4) inhibitor and glucagon-like peptide-1 receptor agonist (GLP-1 Ra), enhance insulin secretion in pancreatic b-cell and showed many benefits in treating diabetes mellitus type 2 but are not a common choice for GDM [117,118].”
From Gestational Diabetes Mellitus—Recent Literature Review (2022) · cites this paper as [117]
In the citing paper
“Evidence that glucose lowering reduces the rates of cardiovascular events and death has not been convincingly shown, 4-6”
From Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes (2015) · cites this paper as [5]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675
Self-citationUniversal Definition of Myocardial Infarction
Thygesen, K., Alpert, J. S., White, H. D., TASK FORCE MEMBERS: Chairpersons: Kristian Thygesen (Denmark), J. S. A. (., Biomarker Group: Allan S. Jaffe, C. (., ECG Group: Bernard Chaitman, C.-O. (., Imaging Group: Richard Underwood, C. (., Intervention Group: Jean-Pierre Bassand, C.-O. (., Clinical Investigation Group: Paul W. Armstrong, C. (., Global Perspective Group: Philip A. Poole-Wilson, C. (., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.187397 · Cited by 4,230
Task Force Members, Thygesen, K., Alpert, J. S., White, H. D., Biomarker Group, Jaffe, A. S., Apple, F. S., Galvani, M., Katus, H. A., Newby, L. K., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm355 · Cited by 2,541
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Discrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
Long-term effects of intensive glucose lowering on cardiovascular outcomes
The ACCORD Study Group (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1006524 · Cited by 1,035
Cardiovascular Biology of the Incretin System
Ussher, J. R., & Drucker, D. J. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1052 · Cited by 530
Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes.
Holst, J. J., & Deacon, C. F. (1998) · Diabetes · doi:10.2337/diabetes.47.11.1663 · Cited by 487
Cited by
Items 701–800 of 1,012
Asymmetric dimethylarginine, a biomarker of cardiovascular complications in diabetes mellitus
Konya, H. (2015) · World Journal of Experimental Medicine · doi:10.5493/wjem.v5.i2.110 · Cited by 39
Schernthaner, G., Schernthaner-Reiter, M. H., & Schernthaner, G.-H. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.04.037 · Cited by 40
Fei, Y., Tsoi, M. F., Kumana, C. R., Cheung, T. T., & Cheung, B. M. Y. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.12.039 · Cited by 35
Arnold, S. V., Echouffo-Tcheugui, J. B., Lam, C. S. P., Inzucchi, S. E., Tang, F., McGuire, D. K., Goyal, A., Maddox, T. M., Sperling, L. S., Fonarow, G. C., et al. (2018) · American Heart Journal · doi:10.1016/j.ahj.2018.05.016 · Cited by 39
Sciacqua, A., Succurro, E., Armentaro, G., Miceli, S., Pastori, D., Rengo, G., & Sesti, G. (2021) · Heart Failure Reviews · doi:10.1007/s10741-021-10182-x · Cited by 38
Effects of newer-generation anti-diabetics on diabetic retinopathy: a critical review
Ntentakis, D. P., Correa, V., Ntentaki, A. M., Delavogia, E., Narimatsu, T., Efstathiou, N. E., & Vavvas, D. G. (2023) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-023-06236-5 · Cited by 43
Kunutsor, S. K., Khunti, K., & Seidu, S. (2023) · Journal of the Royal Society of Medicine · doi:10.1177/01410768231198442 · Cited by 39
Devin, J. K., Pretorius, M., Nian, H., Yu, C., Billings, F. T., & Brown, N. J. (2014) · Journal of the American Heart Association · doi:10.1161/jaha.114.001075 · Cited by 36
“GLP-1(9-36), which promotes endothelium-dependent vasodilation independent of the GLP-1 receptor.”
BackgroundMethodInfluentialGiblett, J. P., Clarke, S. J., Dutka, D. P., & Hoole, S. P. (2016) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2016.03.011 · Cited by 35
Tong, L., & Adler, S. G. (2018) · Postgraduate Medicine · doi:10.1080/00325481.2018.1457397 · Cited by 40
“placebo in patients with a recent history of acute myocardial infarction or unstable angina [101]”
BackgroundThe design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus
Christensen, M., Miossec, P., Larsen, B. D., Werner, U., & Knop, F. K. (2014) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2014.942638 · Cited by 34
“(ORIGIN, SAVOR, EXAMINE, ADVANCE, ACCORD [6-11]) have failed to decrease cardiovascular event rates.”
BackgroundInfluentialDavidson, J. A. (2013) · Endocrine Practice · doi:10.4158/ep12303.ra · Cited by 35
Brenner, C., Kränkel, N., Kühlenthal, S., Israel, L., Remm, F., Fischer, C., Herbach, N., Speer, T., Grabmaier, U., Laskowski, A., et al. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.09.016 · Cited by 39
“cardiovascular death, ischemic stroke or myocardial infarction [46,47] but showed hints that it might be associated with an increased risk for heart failure outcomes [48].”
BackgroundMoon, J.-Y., Woo, J. S., Seo, J.-W., Lee, A., Kim, D. J., Kim, Y., Kim, S.-Y., Lee, K. H., Lim, S., Cheng, X. W., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0150745 · Cited by 34
“, although 28% of patients had congestive heart failure at baseline [3].”
BackgroundRobinson, E., Tate, M., Lockhart, S. M., McPeake, C., O’Neill, K. M., Edgar, K. S., Calderwood, D., Green, B. D., McDermott, B. J., & Grieve, D. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0386-5 · Cited by 39
“Notably, the evident importance of GLP-1(9–36)-mediated actions (together with the known pleiotropic actions of GLP-1 signalling) may at least partly explain the apparently disappointing results of recent large-scale DPP-4 inhibitor trials which failed to demonstrate any significant benefits on cardiovascular outcomes…”
BackgroundResultDiabetes therapies in hemodialysis patients: Dipeptidase-4 inhibitors
Nakamura, Y., Hasegawa, H., Tsuji, M., Udaka, Y., Mihara, M., Shimizu, T., Inoue, M., Goto, Y., Gotoh, H., Inagaki, M., et al. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i6.840 · Cited by 41
DPP4 inhibitors and cardiovascular outcomes: safety on heart failure
Xia, C. Q., Goud, A., D’Souza, J., Dahagam, C., Rao, X., Rajagopalan, S., & Zhong, J. (2017) · Heart Failure Reviews · doi:10.1007/s10741-017-9617-4 · Cited by 37
“Other trials such as the EXAMINE, TECOS, and VIVIDD which studied alogliptin, sitagliptin, and vildagliptin, respectively, have failed to demonstrate similar results [44, 48, 49].”
ResultTreatment of Diabetes in People With Heart Failure
Connelly, K. A., Gilbert, R. E., & Liu, P. X. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.026 · Cited by 38
Management of diabetes mellitus in patients undergoing liver transplantation
Grancini, V., Resi, V., Palmieri, E., Pugliese, G., & Orsi, E. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.01.042 · Cited by 36
“demonstrated the non-inferiority of sitagliptin [211], saxagliptin [212], and alogliptin [213] versus placebo, though there was a signal for increased risk of heart failure with saxagliptin [212] and possibly alogliptin [213] All DDP-4-inhibitors are eliminated by the kidneys, except for linagliptin, which mainly unde…”
BackgroundMechanick, J. I., Adams, S., Davidson, J. A., Fergus, I. V., Galindo, R. J., McKinney, K. H., Petak, S. M., Sadhu, A. R., Samson, S. L., Vedanthan, R., et al. (2019) · Endocrine Practice · doi:10.4158/ps-2019-0080 · Cited by 33
“For instance, among the major cardiovascular outcome trials, 67 to 83% of participants were Caucasians, compared with only 1 to 7% American Islanders/Alaska Natives/others, 3 to 8% African Americans, 7 to 21% Latino/Hispanics, and 9 to 22% Asians (Table 6) (124-133).”
BackgroundPatorno, E., Najafzadeh, M., Pawar, A., Franklin, J. M., Déruaz‐Luyet, A., Brodovicz, K. G., Ortiz, A. J. S., Bessette, L. G., Kulldorff, M., & Schneeweiß, S. (2019) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.103 · Cited by 35
Toxicity of Metformin and Hypoglycemic Therapies
Akhter, M. S., & Uppal, P. (2020) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2019.08.004 · Cited by 40
Berezin, A. Е., & Berezin, A. A. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00835-9 · Cited by 37
Kanie, T., Mizuno, A., Yoneoka, D., Tam, W., Morze, J., Rynkiewicz, A., Xin, Y., Wu, O., & Kwong, J. S. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013650 · Cited by 34
Enzan, N., Matsushima, S., Kaku, H., Tohyama, T., Nagata, T., Ide, T., & Tsutsui, H. (2023) · JACC Asia · doi:10.1016/j.jacasi.2022.09.015 · Cited by 35
Ueng, K., Chiang, C., Chao, T., Wu, Y., Lee, W.-L., Li, Y., Ting, K.-H., Su, C.-H., Lin, H., Su, T., et al. (2023) · PubMed Central · doi:10.6515/acs.202301_39(1).20221103a · Cited by 48
Ou, H., Chang, K., Li, C., & Wu, J. (2017) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13241 · Cited by 36
Tate, M., Chong, A., Robinson, E., Green, B. D., & Grieve, D. J. (2015) · British Journal of Pharmacology · doi:10.1111/bph.12943 · Cited by 33
“…either saxagliptin or apogliptin had no significant effects on their primary composite end points of cardiovascular death, or non-fatal MI/stroke (Scirica et al., 2013; White et al., 2013), although it should be noted that SAVOR-TIMI 53 reported a 27% increase in hospitalization for heart failure.”
BackgroundSafety of antidiabetes medications: An update
Bailey, C. J. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.125 · Cited by 33
“In two recent prospective CV outcome studies, rates of pancreatitis and pancreatic cancer among patients randomly assigned to receive treatment with the DPP-4 inhibitors saxagliptin and alogliptin were statistically indistinguishable from those in patients who received placebo.(18,19) Similar prospective data have not…”
BackgroundResultRaschi, E., Poluzzi, E., Koci, A., Antonazzo, I. C., Marchesini, G., & Ponti, F. D. (2016) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2016.02.006 · Cited by 33
“Recently, the cardiovascular efficacy and safety of dipeptidyl peptidase-4 inhibitors (DPP-4-Is) has been questioned by the results of SAVOR-TIMI and EXAMINE trials, which raised the hypothesis that DPP4-Is may precipitate and/or exacerbate HF [3,4].”
ResultThe regulatory role of DPP4 in atherosclerotic disease
Duan, L., Rao, X., Xia, C. Q., Rajagopalan, S., & Zhong, J. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0558-y · Cited by 39
“In the EXAMINE trial, there were no heart failure-related outcomes reported in their first report although there were 28% of subjects having congestive heart failure at baseline [84].”
BackgroundKwon, C. S., Seoane-Vazquez, E. C., & Rodríguez-Monguió, R. (2018) · BMC Health Services Research · doi:10.1186/s12913-018-2860-0 · Cited by 39
“The sensitivity analyses also included a scenario in which there was no difference in cardiovascular event rates after 2 years from initiation of metformin+DPP-4i and metformin+SU [26, 27].”
BackgroundImpact of dipeptidyl-peptidase 4 inhibitors on cardiovascular diseases
Xie, W., Song, X., & Liu, Z. (2018) · Vascular Pharmacology · doi:10.1016/j.vph.2018.05.010 · Cited by 33
Qian, D., Zhang, T., Zheng, P., Liang, Z., Wang, S., Xie, J., Zhao, L., Zhang, Y., & Situ, B. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0482-5 · Cited by 36
Giugliano, D., Maiorino, M. I., Longo, M., Bellastella, G., Chiodini, P., & Esposito, K. (2019) · Endocrine · doi:10.1007/s12020-019-01931-y · Cited by 35
Webb, D. R., Htike, Z. Z., Swarbrick, D. J., Brady, E. M., Gray, L. J., Biglands, J. D., Gulsin, G. S., Henson, J. J., Khunti, K., McCann, G. P., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14023 · Cited by 37
“Increased hospitalization for heart failure with the DPP-4 inhibitor saxagliptin in the Savor-Timi 53 trial and a non-statistically significant increase in the same outcome in the EXAMINE study of alogliptin provided the original rationale for a potentially sizeable active comparator differential with liraglutide in L…”
ResultTerasaki, M., Yashima, H., Mori, Y., Saito, T., Matsui, T., Hiromura, M., Kushima, H., Osaka, N., Ohara, M., Fukui, T., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21134811 · Cited by 33
Pharmacological interventions for heart failure in people with chronic kidney disease
Lunney, M., Ruospo, M., Natale, P., Quinn, R. R., Ronksley, P. E., Konstantinidis, I., Palmer, S. C., Tonelli, M. A., Strippoli, G. F., & Ravani, P. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012466.pub2 · Cited by 42
Incretins, Diabetes, Pancreatitis and Pancreatic Cancer: What the GI specialist needs to know
Forsmark, C. E. (2015) · Pancreatology · doi:10.1016/j.pan.2015.11.009 · Cited by 36
Harrington, J. L., de Albuquerque Rocha, N., Patel, K. V., Verma, S., & McGuire, D. K. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1035-z · Cited by 32
Incretins and cardiovascular disease: to the heart of type 2 diabetes?
Solini, A., Tricò, D., & Del Prato, S. (2023) · Diabetologia · doi:10.1007/s00125-023-05973-w · Cited by 32
Arvanitakis, K., Koufakis, T., Kalopitas, G., Papadakos, S. P., Kotsa, K., & Germanidis, G. S. (2023) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2023.102935 · Cited by 35
Is HbA1c a valid surrogate for macrovascular and microvascular complications in type 2 diabetes?
Bejan‐Angoulvant, T., Cornu, C., Archambault, P., Tudrej, B. V., Audier, P., Brabant, Y., Gueyffier, F., & Boussageon, R. (2015) · Diabetes & Metabolism · doi:10.1016/j.diabet.2015.04.001 · Cited by 42
Extra-pancreatic effects of incretin-based therapies
Gallwitz, B. (2014) · Endocrine · doi:10.1007/s12020-014-0223-0 · Cited by 35
Kawase, H., Bando, Y., Nishimura, K., Aoyama, M., Monji, A., & Murohara, T. (2016) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2016.06.066 · Cited by 33
“Dipeptidyl peptidase-4 inhibitor (DPP4i) has dominated the new class of anti-diabetic remedies and their cardiovascular safety has been confirmed in terms of major cardiovascular events, namely macrovascular diseases [2][3][4] and heart failure [2][3][5][6]; however, the impact of DPP4i on hypertension clinically rema…”
BackgroundBarkas, F., Elisaf, M., Tsimihodimos, V., & Milionis, H. J. (2016) · Diabetes & Metabolism · doi:10.1016/j.diabet.2016.10.006 · Cited by 32
Tanaka, A., Shimabukuro, M., Okada, Y., Taguchi, I., Yamaoka‐Tojo, M., Tomiyama, H., Teragawa, H., Sugiyama, S., Yoshida, H., Sato, Y., et al. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0532-8 · Cited by 37
Pathophysiology and Prevention of Heart Disease in Diabetes Mellitus
Oktay, A. A., Aktürk, H. K., Esenboğa, K., Javed, F., Polin, N. M., & Jahangir, E. (2017) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2017.05.001 · Cited by 36
Packer, M. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0648-x · Cited by 32
“Nevertheless, many of the large-scale cardiovascular trials have reported the effects of DPP-4 inhibitors on aspects of diabetic nephropathy, specifically changes in urinary protein excretion, in glomerular function over time, and in the risk of progression to end-stage renal disease [47, 48, 84].”
BackgroundScheen, A. J. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.05.007 · Cited by 37
Spencer, N. Y., Yang, Z., Sullivan, J. C., Klein, T., & Stanton, R. C. (2018) · PLoS ONE · doi:10.1371/journal.pone.0200249 · Cited by 35
Mishriky, B. M., Powell, J. R., Wittwer, J. A., Chu, J., Sewell, K. B., Wu, Q., & Cummings, D. M. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13805 · Cited by 32
Webb, D. R., Davies, M. J., Jarvis, J., Seidu, S., & Khunti, K. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107836 · Cited by 36
“DPP-4 inhibitors have demonstrated their cardiovascular safety but have not demonstrated a significant reduction in MACE outcomes within the four CVOTs published to date, involving nearly 50,000 people with Diabetes.”
BackgroundInfluentialVijayakumar, S., Vaduganathan, M., & Butler, J. (2018) · Circulation · doi:10.1161/circulationaha.117.032099 · Cited by 33
The Impact of Antidiabetic Therapies on Diastolic Dysfunction and Diabetic Cardiomyopathy
Gopal, K., Chahade, J. J., Kim, R., & Ussher, J. R. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.603247 · Cited by 38
Roles and Mechanisms of Dipeptidyl Peptidase 4 Inhibitors in Vascular Aging
Cao, F., Wu, K., Zhu, Y., & Bao, Z.-W. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.731273 · Cited by 36
“Data from the EXAMINE trial showed that alogliptin failed to increase the incidence of heart failure outcomes compared with placebo in participants with T2DM after an acute coronary syndrome (131, 132).”
MethodAsymptomatic Diabetic Cardiomyopathy: an Underrecognized Entity in Type 2 Diabetes
Stanton, A. M., Vaduganathan, M., Chang, L., Turchin, A., Januzzi, J. L., & Aroda, V. R. (2021) · Current Diabetes Reports · doi:10.1007/s11892-021-01407-2 · Cited by 37
Recent Advances in the Emerging Therapeutic Strategies for Diabetic Kidney Diseases
Huang, W., Chen, Y., Li, Z., He, F., & Zhang, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810882 · Cited by 36
Targeting cluster of differentiation 26 / dipeptidyl peptidase 4 (CD26/DPP4) in organ fibrosis
Ohm, B., Moneke, I., & Jungraithmayr, W. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15967 · Cited by 36
“However, several large-scale randomized controlled trials have evaluated the clinical cardiovascular outcome of saxagliptin, alogliptin and sitagliptin treat-ment (SAVOR-TIMI 53, EXAMINE and TECOS trials) (Green et al., 2015; Scirica et al., 2013; White et al., 2013).”
BackgroundMethodLyu, Y. S., Oh, S. K., Kim, J. H., Kim, S. Y., & Jeong, M. H. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01914-4 · Cited by 36
“DPP-4i have demonstrated neutral cardiovascular effects in CVOTs [10–13].”
BackgroundSaxagliptin: A Review in Type 2 Diabetes
Dhillon, S. (2015) · Drugs · doi:10.1007/s40265-015-0473-z · Cited by 37
“EXAMINE (n = 5380), which assessed CV outcomes with the addition of alogliptin to existing antihyperglycaemic and CV therapy in a very high-risk population (patients with diabetes who had a recent acute coronary syndrome) [73] and TECOS (n = 14,671), which assessed the longterm CV safety of adding sitagliptin to usual…”
BackgroundMethodResultInfluentialDPP-4 inhibition with linagliptin ameliorates the progression of premature aging in klotho−/− mice
Hasegawa, Y., Hayashi, K., Takemoto, Y., Cheng, C., Takane, K., Lin, B., Komohara, Y., & Kim‐Mitsuyama, S. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0639-y · Cited by 34
“Pooled and meta-analyses with individual DPP-4 inhibitors [3, 4, 7] and a pooled analysis of all DPP-4 inhibitors [8, 9] demonstrated significant reduction of cardiovascular disease by DPP-4 inhibitors, although recent two large clinical trials [10, 11] suggested a neutral effect of this class of drug on cardiovascula…”
MethodHistones and heart failure in diabetes
Yerra, V. G., & Advani, A. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2857-1 · Cited by 34
Common Co-Morbidities in Heart Failure – Diabetes, Functional Mitral Regurgitation and Sleep Apnoea
Coats, A. J. S. (2019) · International Journal of Heart Failure · doi:10.36628/ijhf.2019.0004 · Cited by 35
Saxagliptin, Alogliptin, and Cardiovascular Outcomes
Scirica, B. M., Braunwald, E., & Bhatt, D. L. (2014) · New England Journal of Medicine · doi:10.1056/nejmc1313880 · Cited by 32
Chalmer, T., Almdal, T. P., Vilsbøll, T., & Knop, F. K. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.975205 · Cited by 31
“Moreover, two long-term placebo-controlled trials studying effects of two DDP-4 inhibitors, saxagliptin [52] and alogliptin [53] for a total of 2 and 4 years, respectively, with a total of ~ 20,000 patients, showed no signals of increased rates of pancreatic cancer or pancreatitis.”
BackgroundCardiovascular effects of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes
Koška, J., Sands, M. A., Burciu, C., & Reaven, P. D. (2015) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114562411 · Cited by 35
Gliptins and their target dipeptidyl peptidase 4: implications for the treatment of vascular disease
Remm, F., Franz, W., & Brenner, C. (2015) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvv044 · Cited by 31
Patorno, E., Everett, B. M., Goldfine, A. B., Glynn, R. J., Liu, J., Gopalakrishnan, C., & Kim, S. C. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12665 · Cited by 31
Wang, T., Wang, F., Zhou, J., Tang, H., & Giovenale, S. (2016) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2804 · Cited by 35
Kato, S., Fukui, K., Kirigaya, H., Gyotoku, D., Iinuma, N., Kusakawa, Y., Iguchi, K., Nakachi, T., Iwasawa, T., & Kimura, K. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.08.306 · Cited by 34
Williams, R., de Vries, F., Kothny, W., Șerban, C. I., López‐León, S., Chu, C., & Schlienger, R. G. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12951 · Cited by 31
Liraglutide and cardiovascular outcomes in a real world type 2 diabetes cohort
Mirani, M., Favacchio, G., Serone, E., Lucisano, G., Rossi, M. C., & Berra, C. C. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.09.003 · Cited by 31
Cardiovascular Protection with Anti-hyperglycemic Agents
DEEDWANIA, P. C., & Acharya, T. (2019) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-019-00325-9 · Cited by 33
Furuhashi, M., Sakuma, I., Morimoto, T., Higashiura, Y., Sakai, A., Matsumoto, M., Sakuma, M., Shimabukuro, M., Nomiyama, T., Arasaki, O., et al. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01061-0 · Cited by 34
Potential Effect of DPP-4 Inhibitors Towards Hepatic Diseases and Associated Glucose Intolerance
Sharma, A., Virmani, T., Sharma, A., Chhabra, V., Kumar, G., Pathak, K., & Alhalmi, A. (2022) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s369712 · Cited by 36
“glycemia but without a comparison of proportions of alogliptin and placebo showed non-fatal myocardial infarction or non-fatal stroke.(177) Similarly, other DPP-4 inhibitors also showed some side effects such as musculoskeletal”
ResultWhen metformin is not enough: Pros and cons of SGLT2 and DPP‐4 inhibitors as a second line therapy
Avogaro, A., Delgado, E., & Lingvay, I. (2018) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2981 · Cited by 35
“Similarly, no association with pancreatitis was seen with saxagliptin use in the SAVOR‐TIMI 53 trial(95) or alogliptin use in the EXAMINE trial.(76) However, when data from these large trial was pooled, there was a significantly increased risk for pancreatitis in the DPP‐4 inhibitor treated patients (OR 1.”
ResultSano, M. (2018) · Journal of Cardiology · doi:10.1016/j.jjcc.2018.07.004 · Cited by 34
Lee, W., Kipp, Z. A., Pauss, S. N., Martinez, G. J., Bates, E. A., Badmus, O. O., Stec, D. E., & Hinds, T. D. (2025) · Clinical Science · doi:10.1042/cs20242825 · Cited by 32
“On the other hand, most of the approved DPP4i do not present cardiovascular risk [202–204], but saxagliptin is associated with a higher hospitalization rate for heart failure [205].”
Connelly, K. A., Advani, A., Zhang, Y., Advani, S. L., Kabir, G., Abadeh, A., Desjardins, J., Mitchell, M., Thai, K., & Gilbert, R. E. (2015) · Journal of Diabetes · doi:10.1111/1753-0407.12258 · Cited by 31
Cardiovascular Actions of GLP-1 and Incretin-Based Pharmacotherapy
Avogaro, A., de Kreutzenberg, S. V., & Fadini, G. P. (2014) · Current Diabetes Reports · doi:10.1007/s11892-014-0483-3 · Cited by 31
GLP-1R activation for the treatment of stroke: Updating and future perspectives
Darsalia, V., Nathanson, D., Nyström, T., Klein, T., Sjöholm, Å., & Patrone, C. (2014) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-014-9285-9 · Cited by 31
“However, no superiority of DPP-4 inhibition on cardiovascular endpoints (such as CV death and non-fatal stroke) was apparent from results of two recently published large cardiovascular outcome trials for saxagliptin [127] or alogliptin [128].”
ResultWidlansky, M. E., Puppala, V. K., Suboc, T. M. B., Malik, M. A., Branum, A., Signorelli, K., Wang, J., Ying, R., Tanner, M. J., & Tyagi, S. (2017) · Vascular Medicine · doi:10.1177/1358863x16681486 · Cited by 30
NMDAR antagonists for the treatment of diabetes mellitus—Current status and future directions
Welters, A., Kluppel, C. A., Mrugala, J., Wörmeyer, L., Meißner, T., Mayatepek, E., Heiß, C., Eberhard, D., & Lammert, E. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13017 · Cited by 37
Incretin-based Drugs and the Incidence of Colorectal Cancer in Patients with Type 2 Diabetes
Abrahami, D., Yin, H., Yu, O. H. Y., Pollak, M., & Azoulay, L. (2017) · Epidemiology · doi:10.1097/ede.0000000000000793 · Cited by 34
Li, Y., Tsai, S., Chen, D., Chen, S., Sun, J., Chang, H., Liou, M., & Chen, T. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0655-y · Cited by 31
“Among them, three previous cardiovascular outcome trials of DPP-4 inhibitors (Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus-Thrombolysis in Myocardial Infarction 53 (SAVOR-TIMI 53), Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care (EXAMINE), Trial…”
BackgroundInfluentialMetabolic Karma—The Atherogenic Legacy of Diabetes: The 2017 Edwin Bierman Award Lecture
Cooper, M. E., El‐Osta, A., Allen, T. J., Watson, A. M. D., Thomas, M. C., & Jandeleit-Dahm, K. A. M. (2018) · Diabetes · doi:10.2337/dbi18-0010 · Cited by 33
A practical Bayesian adaptive design incorporating data from historical controls
Psioda, M. A., Soukup, M., & Ibrahim, J. G. (2018) · Statistics in Medicine · doi:10.1002/sim.7897 · Cited by 35
Rosselló, X., Ferreira, J. P., McMurray, J. J. V., Aguilar, D. A., Pfeffer, M. A., Pitt, B., Dickstein, K., Girerd, N., Rossignol, P., Zannad, F. M., et al. (2018) · European Heart Journal Acute Cardiovascular Care · doi:10.1177/2048872618803701 · Cited by 32
Self-citationDeerochanawong, C., Chan, S. P., Matawaran, B. J., Sheu, W. H., Chan, J. C. N., Man, N. H., Suastika, K., Khoo, C. M., Yoon, K., Luk, A. O. Y., et al. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13819 · Cited by 31
Income level and inequality as complement to geographical differences in cardiovascular trials
Ferreira, J. P., Rossignol, P., Dewan, P., Lamiral, Z., White, W. B., Pitt, B., McMurray, J. J. V., & Zannad, F. M. (2019) · American Heart Journal · doi:10.1016/j.ahj.2019.08.019 · Cited by 32
Self-citationSingh, A. K., Gangopadhyay, K. K., & Singh, R. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2020.1736041 · Cited by 33
Menon, V., Kumar, A., Patel, D. R., John, J. S., Riesmeyer, J., Weerakkody, G. J., Ruotolo, G., Wolski, K., McErlean, E. S., Cremer, P. C., et al. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-000943 · Cited by 32
Self-citationChiang, C., Ueng, K.-C., Chao, T., Lin, T., Wu, Y.-J., Wang, K.-L., Sung, S., Yeh, H., Li, Y., Liu, P., et al. (2020) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000359 · Cited by 31
Ferreira, J. P., Lamiral, Z., Bakris, G. L., Mehta, C. R., White, W. B., & Zannad, F. M. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14371 · Cited by 30
“Details of the EXAMINE study design have been previously published.(17,18) A total of 5380 patients with T2D who had a recent ACS were randomly assigned to either alogliptin or placebo.”
BackgroundMethodInfluentialSelf-citationWang, H., Cordiner, R. L. M., Huang, Y., Donnelly, L. A., Hapca, S. M., Collier, A., McKnight, J. A., Kennon, B., Gibb, F. W., McKeigue, P., et al. (2023) · Diabetes Care · doi:10.2337/dc22-1238 · Cited by 35
“Given that DPP4i have been established to be neutral for MACE risk (2,17,27,28) and pioglitazone has been found to have cardioprotective effects (29,30), our findings provide real-world evidence to support the conclusion that SUs prescribed as second-line pharmacotherapy are unlikely to increase CV risk or all-cause d…”
ResultWang, H., Liu, Y., Tian, Q., Yang, J., Lu, R., Zhan, S., Haukka, J. K., & Hong, T. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13177 · Cited by 38
Evidence-Based Management of Diabetes in Older Adults
Mooradian, A. D. (2018) · Drugs & Aging · doi:10.1007/s40266-018-0598-3 · Cited by 34
Singh, A. K., & Singh, R. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1588110 · Cited by 32
Penaforte-Saboia, J. G., Couri, C. E. B., Albuquerque, N. V., Silva, V. L. L., Olegário, N. B. D. C., Fernandes, V. O., & Montenegro, R. M. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s294742 · Cited by 33
Metadata
- Authors
- White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., Wilson, C., Cushman, W. C., & Zannad, F.
- Affiliations
- University of Connecticut (US)
- Brigham and Women's Hospital (US)
- University of Sheffield (GB)
- Cleveland Clinic (US)
- Park Nicollet Health Services (US)
- University of Chicago (US)
- Takeda (United States) (US)
- Harvard University (US)
- Memphis VA Medical Center (US)
- Inserm (FR)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-10-03
- Volume
- 369
- Issue
- 14
- Pages
- 1327-1335
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2127854619
- Cited by
- 2,502
- References
- 23
- Citations by year
- 2026: 43 · 2025: 60 · 2024: 79 · 2023: 107 · 2022: 124 · 2021: 161 · 2020: 225 · 2019: 243 · 2018: 288 · 2017: 279 · 2016: 329 · 2015: 260 · 2014: 248 · 2013: 44
- FWCI
- 231.46
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Figshare (submittedVersion, cc-by)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion, other-oa)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- National Institute for Health and Care Research (NF-SI-0611-10248)
- National Institutes of Health (UL1TR000041)
- Japan Society for the Promotion of Science (24591075)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Keywords
- alogliptin, DPP-4 inhibitors, type 2 diabetes, acute coronary syndrome, major adverse cardiovascular events, cardiovascular safety, non-inferiority, HbA1c, acute myocardial infarction, unstable angina, hypoglycemia
- MeSH terms
- Aged, Angina, Unstable, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Middle Aged, Myocardial Infarction, Piperidines, Uracil, Dipeptidyl-Peptidase IV Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.